Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Common Equity (2016 - 2025)

Veracyte (VCYT) has disclosed Common Equity for 14 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 11.36% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 11.36% year-over-year, with the annual reading at $1.3 billion for FY2025, 11.36% up from the prior year.
  • Common Equity hit $1.3 billion in Q4 2025 for Veracyte, up from $1.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.3 billion in Q4 2025 to a low of $971.2 million in Q2 2021.
  • Historically, Common Equity has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 329.45% in 2021 and later fell 5.32% in 2022.
  • Year by year, Common Equity stood at $1.1 billion in 2021, then fell by 1.94% to $1.1 billion in 2022, then fell by 2.89% to $1.0 billion in 2023, then rose by 12.63% to $1.2 billion in 2024, then rose by 11.36% to $1.3 billion in 2025.
  • Business Quant data shows Common Equity for VCYT at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.